Heron Therapeutics, Inc. Provides Revenue Guidance for the Second Quarter and Full Year 2022
The company expects full-year 2022 net product sales for the oncology care franchise in the range of $89 million to $93 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.44 USD | -0.86% | +7.50% | +102.35% |
05-15 | Transcript : Heron Therapeutics, Inc. - Analyst/Investor Day | |
05-07 | Transcript : Heron Therapeutics, Inc., Q1 2024 Earnings Call, May 07, 2024 |
1st Jan change | Capi. | |
---|---|---|
+102.35% | 523M | |
+67.53% | 62.86B | |
-0.77% | 41.38B | |
+45.66% | 40.38B | |
-10.72% | 27.64B | |
+13.30% | 26.46B | |
-22.79% | 18.9B | |
+4.70% | 12.67B | |
+24.10% | 12.27B | |
+27.41% | 12.07B |